Teritusumab/Telico is usually given for a few days to achieve the best results.

Teritusumab (Teclistamab-cqyv) is a bispecific antibody drug targeting BCMA (B cell maturation antigen) and CD3. Its principle of action is completely different from traditional chemotherapy drugs. It activates the human immune system to kill tumor cells accurately by "connecting" T cells with myeloma cells. This mechanism makes the efficacy of teritusumab often not dependent on short-term high-intensity medication, but to achieve steady control effects through continuous activation of immune responses.

Regardingthe issue of "results within a few days", current clinical experience shows that some patients with multiple myeloma can show signs of improvement within a few weeks of treatment, especially when myeloma-related symptoms such as bone pain, anemia, elevated protein, etc. are relieved. However, due to differences in patients' conditions, genetic backgrounds, and immune status, the drug's onset of effect is not fixed. Typically, the initial phase of teritusumab includes a "dose escalation phase," which generally requires several days to a week of closely monitored injections to gradually reach a maintenance dose. This stage is mainly used to observe immune responses and reduce the risk of immune-related adverse reactions such as cytokine release syndrome (CRS).

After completing the initial dose escalation and entering the maintenance phase, the drug is usually injected in cycles, either weekly or every two weeks. Studies have shown that after about two to three cycles of maintenance treatment, most patients can observe significant therapeutic effects, with a significant reduction in tumor burden and enhanced immune cell activity. The efficacy has since stabilized, and some patients can continue to benefit for more than a year.

It needs to be emphasized that teritusumab is an immunotherapy drug. It is not a rapid drug that "results in a few days". Instead, it relies on the gradual recovery and activation of the immune system to achieve long-term effects. During use, patients should follow the treatment plan prescribed by the doctor, monitor blood and immune indicators regularly, and should not interrupt or change the frequency of dosing on their own.

Reference materials:https://www.tecvayli.com/